跳至主要内容
临床试验/NCT07778888
NCT07778888尚未招募2 期

Phase 2a Masked Trial to Identify the Lowest Effective Concentration of BL1107 for Conjunctival Hyperemia in Patients With Dry Eye Disease

Bausch & Lomb Incorporated0 个研究点目标入组 20 人开始时间: 2026年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
尚未招募
入组人数
20
主要终点
Primary Part 2: Proportion of participants with complete resolution in conjunctival hyperemia at 8 hours, in each evaluated concentration of BL1107

研究概览

简要总结

Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED. Participants will be masked to concentration of BL1107 received.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Documented diagnosis of dry eye disease
  • Conjunctival hyperemia in both eyes, without clinical signs of infection or allergic conjunctivitis

排除标准

  • Any active ocular disease
  • Anticipated wearing of contact lenses during study
  • Additional criteria per protocol

研究组 & 干预措施

BL1107 is sterile ophthalmic solution to be administered at varying concentrations

Experimental

干预措施: BL1107 (Drug)

结局指标

主要结局

Primary Part 2: Proportion of participants with complete resolution in conjunctival hyperemia at 8 hours, in each evaluated concentration of BL1107

时间窗: Assessed at 8 hours

Primary Part 1: Proportion of participants with complete resolution in conjunctival hyperemia at 30 minutes, in each evaluated concentration of BL1107.

时间窗: Assessed at 30 minutes

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验